Compare CASH & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CASH | NRIX |
|---|---|---|
| Founded | 1954 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 2020 |
| Metric | CASH | NRIX |
|---|---|---|
| Price | $76.48 | $18.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $91.00 | $29.08 |
| AVG Volume (30 Days) | 219.1K | ★ 1.5M |
| Earning Date | 01-22-2026 | 02-12-2026 |
| Dividend Yield | ★ 0.27% | N/A |
| EPS Growth | ★ 9.29 | N/A |
| EPS | ★ 7.87 | N/A |
| Revenue | ★ $780,120,000.00 | $83,687,000.00 |
| Revenue This Year | $10.95 | $59.40 |
| Revenue Next Year | $4.75 | N/A |
| P/E Ratio | $9.50 | ★ N/A |
| Revenue Growth | 5.66 | ★ 48.32 |
| 52 Week Low | $64.45 | $8.18 |
| 52 Week High | $86.00 | $22.50 |
| Indicator | CASH | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 61.03 | 54.89 |
| Support Level | $73.08 | $17.97 |
| Resistance Level | $75.48 | $19.55 |
| Average True Range (ATR) | 1.67 | 0.93 |
| MACD | 0.14 | -0.12 |
| Stochastic Oscillator | 95.42 | 62.29 |
Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.